Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort
The pharmaceutical litigation landscape has seen its share of blockbuster cases—from opioid multidistrict litigations to the ongoing Paraquat Parkinson’s claims. But a new California lawsuit (Brown v. Johnson & Johnson et al.) could revive two legacy antipsychotics with a startling twist: breast cancer allegations tied to prolactin elevation. The Plot Twist: From Gynecomastia to Oncology For …
Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort Read More »